Opinion|Videos|December 13, 2024
Talquetamab Step-Up Dosing Strategies and CRS Monitoring
Author(s)Binod Dhakal, MD, MS
Panelist discusses how talquetamab’s step-up dosing strategy aims to mitigate cytokine release syndrome, a common immunologic toxicity. The reported grade 1 CRS with altered taste and dry mouth represents a mild manifestation compared with the MonumenTAL-1 trial, where the initial SUD schedule showed varying CRS rates. Real-world evidence has largely validated trial findings, though alternative SUD approaches may offer different risk-benefit profiles. The optimal SUD strategy continues to evolve as clinical experience expands, balancing efficacy with tolerability.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- Following the second step-up dose, the patient experiences grade 1 cytokine release syndrome (CRS), reporting altered taste and dry mouth.
- Please briefly discuss CRS, step-up dosing (SUD), and initial challenges when using talquetamab in this setting.
- How do these findings compare with real-world evidence?
- How do alternative SUD strategies impact CRS outcomes from MonumenTAL-1?
Advertisement
Related to this article
During a live event, Sikander Ailawadhi, MD, and participants considered a case patient with relapsed multiple myeloma after a quadruplet induction who declined CAR T-cell therapy.
The UK's OPTIMUM trial showed significant differences with a more aggressive treatment regimen for high-risk newly diagnosed multiple myeloma, based on long-term follow-up.
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Approves Imlunestrant Plus Abemaciclib in ESR1-Mutated Breast Cancer
2
Daraxonrasib Combo Receives FDA Breakthrough Status in First-Line PDAC
3
Mosunetuzumab Combo Improves PFS in R/R Follicular Lymphoma
4
FDA Launches Expedited IND Pilot to Speed First-in-Human Trials
5